Psychemedics Corporation (PMD)

NASDAQ
5.560
+0.010(+0.18%)
  • Volume:
    3,795
  • Day's Range:
    5.510 - 5.620
  • 52 wk Range:
    4.850 - 7.500
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

PMD Overview

Prev. Close
5.55
Day's Range
5.51-5.62
Revenue
19.54M
Open
5.531
52 wk Range
4.85-7.5
EPS
-0.36
Volume
3,795
Market Cap
31.38M
Dividend (Yield)
0.28
(5.11%)
Average Vol. (3m)
6,095
P/E Ratio
-15.44
Beta
0.554
1-Year Change
-22.88%
Shares Outstanding
5,644,696
Next Earnings Date
Mar 07, 2023
What is your sentiment on Psychemedics?
or
Market is currently closed. Voting is open during market hours.

Psychemedics Corporation News

  • Psychemedics reports Q3 results
    • BySeeking Alpha-

    Psychemedics (NASDAQ:PMD): Q3 GAAP EPS of $0.23.Revenue of $11M (+10.0% Y/Y)Press ReleaseNow read: IQVIA Holdings, Inc. 2018 Q3 - Results - Earnings Call SlidesOriginal article

  • Psychemedics declares $0.15 dividend
    • BySeeking Alpha-

    Psychemedics (NASDAQ:PMD) declares $0.15/share quarterly dividend, in line with previous.Forward yield 3.61%Payable Nov. 17; for shareholders of record Nov. 6; ex-div Nov. 3.Now...

  • Psychemedics reports Q3 results
    • BySeeking Alpha-

    Psychemedics (NASDAQ:PMD): Q3 EPS of $0.25Revenue of $10M (-15.3% Y/Y)Press ReleaseNow read: Big Pharma Duet Greets REIT Atop 'Safer' Dividend Healthcare Pack For Gains In...

Psychemedics Corporation Company Profile

Psychemedics Corporation Company Profile

Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. The Company’s testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customize its enzyme immunoassay (EIA) procedures to drug test hair samples. The Company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines, opiates, synthetic cannabinoids, benzodiazepines, nicotine and fentanyl. The Company markets its corporate drug testing services through its own sales force, distributors and webinars. The Company markets its home drug testing service, PDT-90, through the Internet.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell